In patients with GBM, although CAR-T cells targeting EGFRvIII decreased the number of EGFRvIII-expressing tumor cells, subsequent analysis of surgical samples showed a high level of wild-type EGFR in the tumor site. This evidence concerns the gene EGFR and glioblastoma.